NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. (“TFF” or the “Company”) (NASDAQ: TFFP). Those investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, extension 7980.

The investigation concerns whether TFF and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On November 1, 2022, TFF issued a press release announc[ing] Program updates for the Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC) clinical programs. TFF stated that “[w]We expect to deliver preliminary patient data from the Phase 2 study for TFF VORI in Q1 2023 and for TFF TAC in Q2 2023,” stating, “[t]The data release timing has been updated due to multiple challenges related to staff shortages, shipping and delays in the global supply chain.” Following this news, TFF’s stock price fell sharply in after-market trading.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980